Research Analysts Set Expectations for BioDelivery Sciences International, Inc.’s Q1 2020 Earnings (BDSI)

Share on StockTwits

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Stock analysts at William Blair issued their Q1 2020 earnings per share (EPS) estimates for BioDelivery Sciences International in a note issued to investors on Thursday, April 11th. William Blair analyst T. Lugo forecasts that the specialty pharmaceutical company will post earnings per share of $0.00 for the quarter. William Blair also issued estimates for BioDelivery Sciences International’s Q2 2020 earnings at $0.01 EPS, Q3 2020 earnings at $0.03 EPS and Q4 2020 earnings at $0.05 EPS.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, December 27th. BidaskClub upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Friday, January 11th. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of BioDelivery Sciences International in a research note on Friday, March 15th. Finally, Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $5.79.

NASDAQ BDSI opened at $4.81 on Monday. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. The company has a market cap of $350.49 million, a P/E ratio of -6.59 and a beta of 0.46. BioDelivery Sciences International has a 52 week low of $1.70 and a 52 week high of $5.37.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $18.03 million during the quarter, compared to analyst estimates of $16.15 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $4.60, for a total transaction of $36,800.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $5.00, for a total transaction of $10,000,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,048,050 shares of company stock worth $10,241,990 in the last 90 days. 13.26% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the business. Advisor Group Inc. increased its stake in BioDelivery Sciences International by 56.3% during the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,943 shares in the last quarter. Squarepoint Ops LLC acquired a new position in BioDelivery Sciences International during the 4th quarter valued at approximately $147,000. Raymond James & Associates increased its stake in BioDelivery Sciences International by 14.9% during the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,000 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in BioDelivery Sciences International during the 3rd quarter valued at approximately $255,000. Finally, Virtu Financial LLC acquired a new position in BioDelivery Sciences International during the 1st quarter valued at approximately $300,000. Institutional investors and hedge funds own 56.89% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: Investing strategies using the yield curve

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Scout24  Given a €50.00 Price Target by JPMorgan Chase & Co. Analysts
Scout24 Given a €50.00 Price Target by JPMorgan Chase & Co. Analysts
Independent Research Reiterates €74.00 Price Target for Fresenius Medical Care AG & Co. KGaA
Independent Research Reiterates €74.00 Price Target for Fresenius Medical Care AG & Co. KGaA
Daimler  PT Set at €70.00 by Deutsche Bank
Daimler PT Set at €70.00 by Deutsche Bank
1&1 Drillisch  PT Set at €34.00 by Independent Research
1&1 Drillisch PT Set at €34.00 by Independent Research
ADO Properties  PT Set at €48.00 by Jefferies Financial Group
ADO Properties PT Set at €48.00 by Jefferies Financial Group
Siltronic  Given a €71.00 Price Target by Kepler Capital Markets Analysts
Siltronic Given a €71.00 Price Target by Kepler Capital Markets Analysts


© 2006-2019 Ticker Report